Radiosynthesis of 55Co- and 58mCo-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy
Article first published online: 30 AUG 2011
Copyright © 2011 John Wiley & Sons, Ltd.
Journal of Labelled Compounds and Radiopharmaceuticals
Volume 54, Issue 12, pages 758–762, October 2011
How to Cite
Thisgaard, H., Olesen, M. L. and Dam, J. H. (2011), Radiosynthesis of 55Co- and 58mCo-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy. J Label Compd Radiopharm, 54: 758–762. doi: 10.1002/jlcr.1919
- Issue published online: 11 NOV 2011
- Article first published online: 30 AUG 2011
- Manuscript Accepted: 14 JUL 2011
- Manuscript Revised: 19 MAY 2011
- Manuscript Received: 2 MAR 2011
- radionuclide therapy;
- Auger electrons;
The SPECT compound 57Co-DOTATOC has recently been shown to have the highest affinity ever found for somatostatin receptor subtype 2. Moreover, the internalization rate into the tumour cell line AR42J was also the highest found for any somatostatin-based radiopharmaceutical. We here present a method to prepare the positron emission tomography compound 55Co-DOTATOC as a new promising radiopharmaceutical for positron emission tomography via solid target irradiations of enriched Fe-metal. Also, the new, potent Auger-electron-emitting radioisotope 58mCo and the resulting therapeutic compound 58mCo-DOTATOC as candidate for targeted radionuclide therapy of somatostatin receptor-positive tumours have been prepared with high yield and high radiochemical purity. Copyright © 2011 John Wiley & Sons, Ltd.